
Scientists at the Massachusetts Institute of Technology (MIT) have developed new "nanotube longboats" that can deliver toxic drugs to cancer cells, while sparing healthy cells.
Lead researcher Stephen Lippard has revealed that the "boats" have been created by attaching a modified version of potent cancer drug cisplatin and folic acid to carbon nanotubes.
Advertisement
Experiments with the boats have so far shown that they can kill cells with folic acid receptors more effectively than cells without them, he says.
Since the receptors are most numerous on cancer cells, Lippard hopes that the new approach can target tumours in the body and spare healthy cells.
Cancer drug paclitaxil has also been loaded onto longboats.
The researchers say that they were too big to squeeze through the pores in normal blood vessels, but small enough to get into the vessels that feed tumours.
The findings of the study have been published in the Journal of the American Chemical Society, and Cancer Research.
Source: ANI
LIN
Advertisement
Cancer drug paclitaxil has also been loaded onto longboats.
The researchers say that they were too big to squeeze through the pores in normal blood vessels, but small enough to get into the vessels that feed tumours.
The findings of the study have been published in the Journal of the American Chemical Society, and Cancer Research.
Source: ANI
LIN
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News

Researchers found a pathway linked to allergies that, when blocked, triggers antitumor immunity in lung cancer mouse models.

The occurrence of epimutations early in pregnancy challenges traditional theories related to carcinogenesis and the risk of developing breast cancer.

More affected relatives, higher lung cancer risk; participants with affected mothers or siblings faced increased risk.

Colorectal cancer can be lowered by up to 7% by increasing dietary consumption of folate rich foods like spinach, broccoli or taking folate supplements.

The effects and mechanisms of microRNA-451a (miR-451a), which hinders the progression of gemcitabine-resistant biliary tract cancers, are under study.